# Performance Status During Treatment With Pemetrexed in Patients With NSCLC

> **NCT00540241** · — · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 542 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00540241
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-10
- **Final completion:** 2010-03
- **Target enrollment:** 542 (ACTUAL)
- **Last updated:** 2011-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540241, "Performance Status During Treatment With Pemetrexed in Patients With NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00540241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*